Targeting Wolman Disease and Cholesteryl Ester Storage Disease: Disease Pathogenesis and Therapeutic Development
| Autor: | Wei Zheng, Francis Aguisanda, Natasha Thorne |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Malabsorption
Hepatosplenomegaly Lysosomal storage disease Disease Biochemistry Article chemistry.chemical_compound Lysosome Genetics medicine Molecular Biology Wolman disease Cholesterol High-throughput screening Cholesteryl ester storage disease medicine.disease Pathophysiology Induced pluripotent stem cells medicine.anatomical_structure chemistry Failure to thrive Immunology Molecular Medicine medicine.symptom Cell-based disease model |
| Zdroj: | Current Chemical Genomics and Translational Medicine |
| ISSN: | 2213-9885 |
| DOI: | 10.2174/2213988501711010001 |
| Popis: | Wolman disease (WD) and cholesteryl ester storage disease (CESD) are lysosomal storage diseases (LSDs) caused by a deficiency in lysosomal acid lipase (LAL) due to mutations in the LIPA gene. This enzyme is critical to the proper degradation of cholesterol in the lysosome. LAL function is completely lost in WD while some residual activity remains in CESD. Both are rare diseases with an incidence rate of less than 1/100,000 births for WD and approximate 2.5/100,000 births for CESD. Clinical manifestation of WD includes hepatosplenomegaly, calcified adrenal glands, severe malabsorption and a failure to thrive. As in CESD, histological analysis of WD tissues reveals the accumulation of triglycerides (TGs) and esterified cholesterol (EC) in cellular lysosomes. However, the clinical presentation of CESD is less severe and more variable than WD. This review is to provide an overview of the disease pathophysiology and the current state of therapeutic development for both of WD and CESD. The review will also discuss the application of patient derived iPSCs for further drug discovery. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|